Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes treatments in oncology, inflammation, and autoimmune diseases. Valued at a market cap of $16.5 billion, the company’s portfolio includes drugs such as Jakafi, Monjuvi, Pemazyre, and Opzelura. Companies valued at$10 billion or more are typically classified as “large-cap stocks,” and Incyte fits the label perfectly, with its market cap exceeding this threshold, underscoring its s ...